Normal view MARC view ISBD view

Fluoxetine in treatment of adolescent patients with Autism : A longtudinal open trial.

By: S.Hossein Fatemi ... et al.
Series: Journal of Autism and Developmental Disorders 28 (4) Aug 1998: 303-307.Publisher: 1998Subject(s): ADOLESCENTS | AUTISM | FLUOXETINESummary: Retrospective chart reviews of seven adolescent and young adults with autistic disorder treated with fluxoxetine alone or in combination with other medications were performed. Patients ages varied from 9-20 years. Fluxoetin doses ranged from 20-80 mg per day. Duration of treatment ranged from 1.3-32 months. Patients symptoms were montiored using the Aberrant Behaviour Checklist (ABC) rating scale during every visit. Side effects included initial appetite suppression, vivid dreams, and hyperactivity. Improvement from baseline was seen in four subscales: irritability (21%) Lethargy subscales improved significantly during treatment. Hyperactivity subscale increased by 14% but did not attain statistical significance. Fluoxetine appears to have important behavioural effects in treatment of clinic-referred autistic children. Future double-blind placebo controlled studies evaluating core and associated symptom response with fluxotine are warranted. [AJ].
Tags from this library: No tags from this library for this title. Log in to add tags.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode Item holds
Article IHC Library
Article (Browse shelf) Available (Article available on request) 10502
Total holds: 0

Retrospective chart reviews of seven adolescent and young adults with autistic disorder treated with fluxoxetine alone or in combination with other medications were performed. Patients ages varied from 9-20 years. Fluxoetin doses ranged from 20-80 mg per day. Duration of treatment ranged from 1.3-32 months. Patients symptoms were montiored using the Aberrant Behaviour Checklist (ABC) rating scale during every visit. Side effects included initial appetite suppression, vivid dreams, and hyperactivity. Improvement from baseline was seen in four subscales: irritability (21%) Lethargy subscales improved significantly during treatment. Hyperactivity subscale increased by 14% but did not attain statistical significance. Fluoxetine appears to have important behavioural effects in treatment of clinic-referred autistic children. Future double-blind placebo controlled studies evaluating core and associated symptom response with fluxotine are warranted. [AJ].

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha

//